All these circumstances collectively indicate that targeting ADORA2A holds significant promise in the treatment of pathological angiogenesis in vision-threatening eye diseases and many other diseases highly dependent on pathological angiogenesis. This evidence concerns the gene ADORA2A and eye disorder.